ELRIG Announces Drug Discovery 2014 Programme and Pre-Conference SLAS Short Courses
News Aug 04, 2014
ELRIG (European Laboratory Robotics Interest Group) announced details of the programme for Drug Discovery 2014. The event provides an opportunity for scientists from all fields of early stage drug discovery to network throughout the two days, and to hear world class speakers present on the latest challenges, opportunities and advances. Registration for the event is free, and delegates can register online at www.elrig.org.
The 2014 event will feature a programme of scientific presentations, an exhibition area with around 100 vendor booths, networking opportunities, poster sessions, Dragons Den, Authors Workshop, Innovation Zone, Media Area and Careers Zone, and for the first time a series of Core Technologies Workshops, providing a more informal, interactive environment in which to discuss key issues and future directions, coordinated by leaders in their fields. There will be eight Scientific Sessions altogether, with three new sessions covering cutting-edge topics: Phenotypic Discovery & Cellular Imaging; Chemical Innovation in Lead Discovery; and Neuroscience Drug Targets.
The Scientific Sessions will feature presentations from leading scientists, including the show keynote address from Dr Susan Galbraith, Head of Oncology at AstraZeneca, on ‘Genetic drivers of cancer growth and resistance mechanisms’. Other speakers include: Lorenz Mayr, AstraZeneca; Daniela Gabriel, Novartis; Olli Kallioniemi, FIMM, Helsinki; Stefan Offermans, Max Planck; Dario Neri, ETH, Zurich; Lutz Jermuntas, MedImmune; and Eric Karran, Alzheimers Research UK.
For a full listing of speakers and sessions, visit http://elrig.org/drug-discovery-2014-overview/
In partnership with SLAS, this year’s conference will be preceded by a series of one day short courses, which will take place on Monday 1st September. For more information and to book a place, visit www.elrig.org/portfolio/slas-short-courses-drug-discovery-2014. The courses comprise:
• Course 1: Introduction to Laboratory Automation
• Course 2: High Content Screening: Instrumentation, Assay Development, Screening, Image and Data Analysis
• Course 3: Establishing Cell-Based Assays and Implementing 3D Culture Models for Screening and drug testing
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.